Literature DB >> 31540978

ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?

Dongqing Yan1, Anthony D Pomicter1, Thomas O'Hare1, Michael W Deininger2.   

Abstract

BCR-ABL1 transcripts at imatinib cessation were quantified by droplet digital PCR (ddPCR) for 175 patients on the STIM2 trial. Patients with BCR-ABL1 transcripts below a defined cutoff had a 12-month molecular recurrence rate of 46% versus 68% for those above the cutoff. Implications of using ddPCR in forecasting successful imatinib cessation are discussed.See related article by Nicolini et al., p. 6606. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID： 31540978      PMCID： PMC6858959          DOI： 10.1158/1078-0432.CCR-19-2270

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  7 in total

1.  Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Authors:  Susanne Saussele; Johan Richter; Joelle Guilhot; Franz X Gruber; Henrik Hjorth-Hansen; Antonio Almeida; Jeroen J W M Janssen; Jiri Mayer; Perttu Koskenvesa; Panayiotis Panayiotidis; Ulla Olsson-Strömberg; Joaquin Martinez-Lopez; Philippe Rousselot; Hanne Vestergaard; Hans Ehrencrona; Veli Kairisto; Katerina Machová Poláková; Martin C Müller; Satu Mustjoki; Marc G Berger; Alice Fabarius; Wolf-Karsten Hofmann; Andreas Hochhaus; Markus Pfirrmann; Francois-Xavier Mahon
Journal:  Lancet Oncol       Date:  2018-05-04       Impact factor: 41.316

2.  Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission.

Authors:  Naranie Shanmuganathan; Jodi A Braley; Agnes S M Yong; Devendra K Hiwase; David T Yeung; David M Ross; Timothy P Hughes; Susan Branford
Journal:  Blood       Date:  2019-04-09       Impact factor: 22.113

3.  Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.

Authors:  Franck Emmanuel Nicolini; Stéphanie Dulucq; Lisa Boureau; Pascale Cony-Makhoul; Aude Charbonnier; Martine Escoffre-Barbe; Françoise Rigal-Huguet; Valérie Coiteux; Bruno Varet; Viviane Dubruille; Pascal Lenain; Philippe Rousselot; Delphine Rea; Agnès Guerci-Bresler; Laurence Legros; Jixing Liu; Martine Gardembas; Jean-Christophe Ianotto; Pascal Turlure; Hyacinthe Johnson-Ansah; Juliana Martiniuc; Henry Jardel; Bertrand Joly; Patricia Zunic; Tawfiq Henni; Bruno Villemagne; Marc G Berger; Emilie Cayssials; François Guilhot; Fabrice Larosa; Joëlle Guilhot; Gabriel Etienne; François-Xavier Mahon
Journal:  Clin Cancer Res       Date:  2019-07-10       Impact factor: 12.531

4.  Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

Authors:  Laurence Legros; Franck E Nicolini; Gabriel Etienne; Philippe Rousselot; Delphine Rea; Stéphane Giraudier; Agnès Guerci-Bresler; Françoise Huguet; Martine Gardembas; Martine Escoffre; Jean-Christophe Ianotto; Marie-Pierre Noël; Bruno R Varet; Thomas Pagliardini; Irit Touitou; Stéphane Morisset; Francois-Xavier Mahon
Journal:  Cancer       Date:  2017-07-25       Impact factor: 6.860

5.  CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

Authors:  Amy Hughes; Jade Clarson; Carine Tang; Ljiljana Vidovic; Deborah L White; Timothy P Hughes; Agnes S M Yong
Journal:  Blood       Date:  2017-01-03       Impact factor: 22.113

6.  Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Authors:  M Ilander; U Olsson-Strömberg; H Schlums; J Guilhot; O Brück; H Lähteenmäki; T Kasanen; P Koskenvesa; S Söderlund; M Höglund; B Markevärn; A Själander; K Lotfi; A Dreimane; A Lübking; E Holm; M Björeman; S Lehmann; L Stenke; L Ohm; T Gedde-Dahl; W Majeed; H Ehrencrona; S Koskela; S Saussele; F-X Mahon; K Porkka; H Hjorth-Hansen; Y T Bryceson; J Richter; S Mustjoki
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

7.  Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.

Authors:  Delphine Rea; Guylaine Henry; Zena Khaznadar; Gabriel Etienne; François Guilhot; Franck Nicolini; Joelle Guilhot; Philippe Rousselot; Françoise Huguet; Laurence Legros; Martine Gardembas; Viviane Dubruille; Agnès Guerci-Bresler; Aude Charbonnier; Frédéric Maloisel; Jean-Christophe Ianotto; Bruno Villemagne; François-Xavier Mahon; Hélène Moins-Teisserenc; Nicolas Dulphy; Antoine Toubert
Journal:  Haematologica       Date:  2017-05-18       Impact factor: 9.941
  7 in total
  1 in total

1.  Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.

Authors:  Tariq I Mughal; Bethan Psaila; Daniel J DeAngelo; Giuseppe Saglio; Richard A Van Etten; Jerald P Radich
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.